Top Page
Polarean Imaging
(LSE:POLX)
Polarean Imaging (POLX) vs. iShares MSCI United Kingdom ETF (EWC)
Polarean Imaging Business Overview & Revenue Model
Polarean Imaging Earnings Call Summary
Polarean Imaging Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.42M | 890.93K | 1.03M | 1.19M | 1.06M |
| Gross Profit | 358.61K | 335.48K | 348.28K | 508.02K | 710.47K |
| EBITDA | -5.92M | -10.93M | -12.84M | -13.06M | -5.73M |
| Net Income | -6.68M | -11.88M | -13.91M | -14.02M | -6.55M |
Balance Sheet | |||||
| Total Assets | 15.79M | 10.88M | 22.54M | 34.53M | 10.88M |
| Cash, Cash Equivalents and Short-Term Investments | 12.11M | 6.17M | 16.45M | 28.87M | 6.28M |
| Total Debt | 503.79K | 216.69K | 358.84K | 489.79K | 221.43K |
| Total Liabilities | 3.65M | 2.58M | 3.23M | 2.79M | 2.15M |
| Stockholders Equity | 12.14M | 8.30M | 19.30M | 31.74M | 8.73M |
Cash Flow | |||||
| Free Cash Flow | -4.33M | -10.51M | -12.32M | -12.79M | -5.86M |
| Operating Cash Flow | -4.17M | -10.43M | -12.26M | -12.25M | -5.79M |
| Investing Cash Flow | -154.66K | 219.98K | -63.95K | -541.45K | -65.53K |
| Financing Cash Flow | 9.02M | -140.04K | 147.62K | 35.07M | 10.18M |
Polarean Imaging Technical Analysis
Polarean Imaging Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | £6.41M | ― | -5.41% | ― | -20.31% | -19.35% | |
47 Neutral | £22.44M | ― | -87.30% | ― | ― | 71.17% | |
45 Neutral | £18.38M | ― | -51.63% | ― | 31.78% | 10.27% | |
44 Neutral | £45.89M | ― | -38.49% | ― | ― | ― | |
40 Neutral | $4.83M | ― | -80.95% | ― | 33.86% | 76.08% |
Polarean Imaging Corporate Events
Polarean Imaging plc has submitted a new Phase III clinical trial protocol to the FDA to expand the indication of its XENOVIEW® contrast agent to include quantitative gas-exchange imaging. This expansion aims to enhance the clinical utility of XENOVIEW by enabling comprehensive lung function assessment, which could significantly impact the diagnosis and treatment of various pulmonary diseases. The FDA’s review of this protocol is expected to conclude by Q4 2025, marking a critical milestone in Polarean’s growth strategy and its mission to transform pulmonary imaging.
The most recent analyst rating on (GB:POLX) stock is a Buy with a £8.00 price target. To see the full list of analyst forecasts on Polarean Imaging stock, see the GB:POLX Stock Forecast page.
Polarean Imaging has entered into a Representative Agreement with Ascend Imaging to promote and sell its Xenon MRI platform in four US states. This partnership aims to enhance Polarean’s market reach and commercial momentum by leveraging Ascend Imaging’s expertise in radiology and strong customer relationships, supporting Polarean’s strategic expansion in the US market.
The most recent analyst rating on (GB:POLX) stock is a Buy with a £8.00 price target. To see the full list of analyst forecasts on Polarean Imaging stock, see the GB:POLX Stock Forecast page.
Polarean Imaging Plc announced that the FDA has approved the expansion of its XENOVIEW® indication to include children aged six and older, increasing the number of eligible patients by approximately one million. This approval allows for broader access to the company’s technology, enhancing its clinical utility and market reach. The introduction of new Dose Delivery Bag sizes for younger patients and updates to the HPX Polarisation Measurement Station further support the company’s commitment to advancing lung imaging and providing personalized care for children with chronic respiratory conditions.
The most recent analyst rating on (GB:POLX) stock is a Buy with a £8.00 price target. To see the full list of analyst forecasts on Polarean Imaging stock, see the GB:POLX Stock Forecast page.
Polarean Imaging announced that Dr. Bastiaan Driehuys, its Chief Scientific Officer, received the 2025 American Thoracic Society Respiratory Health Award for his pioneering work in Xenon MRI technology. This recognition highlights the impact of Dr. Driehuys’ contributions to pulmonary imaging, which have advanced the science and improved patient outcomes by enabling earlier detection and better treatment planning for respiratory conditions.
The most recent analyst rating on (GB:POLX) stock is a Buy with a £8.00 price target. To see the full list of analyst forecasts on Polarean Imaging stock, see the GB:POLX Stock Forecast page.
Polarean Imaging plc’s Xenon MRI technology will be prominently featured at the American Thoracic Society’s 2025 Respiratory Innovation Summit and International Conference, highlighting its growing recognition as a pivotal tool in respiratory care. With over 30 presentations from leading clinical sites, the technology’s versatility across various respiratory conditions is showcased, reinforcing its role in both clinical care and trials. This presence underscores Polarean’s position at the forefront of respiratory medicine, as the company continues to engage with industry leaders and stakeholders to advance functional lung imaging.
The most recent analyst rating on (GB:POLX) stock is a Buy with a £8.00 price target. To see the full list of analyst forecasts on Polarean Imaging stock, see the GB:POLX Stock Forecast page.
Polarean Imaging has announced a continued collaboration with Philips to expand the use of advanced Xenon lung MRI technology for children with chronic obstructive lung disease. This partnership is expected to enhance Polarean’s market position by broadening the application of its innovative imaging solutions, potentially benefiting stakeholders by addressing significant healthcare needs in pediatric respiratory medicine.
The most recent analyst rating on (GB:POLX) stock is a Buy with a £8.00 price target. To see the full list of analyst forecasts on Polarean Imaging stock, see the GB:POLX Stock Forecast page.